NasdaqGM - Nasdaq Real Time Price USD

Intellia Therapeutics, Inc. (NTLA)

Compare
10.99
-0.30
(-2.66%)
At close: January 24 at 4:00:00 PM EST
10.96
-0.03
(-0.26%)
After hours: January 24 at 7:50:43 PM EST
Loading Chart for NTLA
DELL
  • Previous Close 11.29
  • Open 11.25
  • Bid 10.93 x 1100
  • Ask 11.03 x 900
  • Day's Range 10.89 - 11.46
  • 52 Week Range 9.25 - 34.87
  • Volume 1,965,002
  • Avg. Volume 2,841,493
  • Market Cap (intraday) 1.119B
  • Beta (5Y Monthly) 1.81
  • PE Ratio (TTM) --
  • EPS (TTM) -5.45
  • Earnings Date Feb 20, 2025 - Feb 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 52.88

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

www.intelliatx.com

526

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NTLA

View More

Performance Overview: NTLA

Trailing total returns as of 1/24/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

NTLA
3.68%
S&P 500
3.29%

1-Year Return

NTLA
57.39%
S&P 500
25.42%

3-Year Return

NTLA
86.52%
S&P 500
38.73%

5-Year Return

NTLA
22.11%
S&P 500
83.47%

Compare To: NTLA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NTLA

View More

Valuation Measures

As of 1/24/2025
  • Market Cap

    1.12B

  • Enterprise Value

    562.82M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    24.49

  • Price/Book (mrq)

    1.16

  • Enterprise Value/Revenue

    13.06

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -27.81%

  • Return on Equity (ttm)

    -52.23%

  • Revenue (ttm)

    43.09M

  • Net Income Avi to Common (ttm)

    -522.28M

  • Diluted EPS (ttm)

    -5.45

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    658.11M

  • Total Debt/Equity (mrq)

    10.56%

  • Levered Free Cash Flow (ttm)

    -184.96M

Research Analysis: NTLA

View More

People Also Watch